Evidence map›Paper›PMID 41157183›Full record

ReviewLife (Basel, Switzerland)2025

The Gut Microbiota-Sex-Immunity Axis in Non-Communicable Diseases.

Mario Caldarelli, Pierluigi Rio, Laura Franza, Sebastiano Cutrupi, Martina Menegolo, Francesco Franceschi, Antonio Gasbarrini, Giovanni Gambassi, Rossella Cianci

Abstract readReview
In one paragraph

Review in Life (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mario CaldarelliDepartment of Translational Medicine and Surgery, Catholic University of Sacred Heart, 00168 Rome, Italy.ORCID 0000-0001-5308-7072
Pierluigi RioDepartment of Translational Medicine and Surgery, Catholic University of Sacred Heart, 00168 Rome, Italy.ORCID 0000-0002-8659-3091
Laura FranzaFondazione Policlinico Universitario A. Gemelli, Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), 00168 Rome, Italy.ORCID 0000-0001-8638-7565
Sebastiano CutrupiDepartment of Translational Medicine and Surgery, Catholic University of Sacred Heart, 00168 Rome, Italy.
Martina MenegoloDepartment of Translational Medicine and Surgery, Catholic University of Sacred Heart, 00168 Rome, Italy.
Francesco FranceschiFondazione Policlinico Universitario A. Gemelli, Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), 00168 Rome, Italy.
Antonio GasbarriniDepartment of Translational Medicine and Surgery, Catholic University of Sacred Heart, 00168 Rome, Italy.ORCID 0000-0002-6230-1779
Giovanni GambassiDepartment of Translational Medicine and Surgery, Catholic University of Sacred Heart, 00168 Rome, Italy.
Rossella CianciDepartment of Translational Medicine and Surgery, Catholic University of Sacred Heart, 00168 Rome, Italy.ORCID 0000-0001-5378-8442

Funding

Italian Ministry of Health PNRR Mission 6 initiative on Health (Project no. PNRR-MAD-2022-12376383, CIMA).
6 · The paper itself

Abstract

Non-communicable diseases (NCDs), including cancer and autoimmune, metabolic, cardiovascular, and neurodegenerative diseases, represent the leading cause of death globally and a growing healthcare burden. The gut microbiota (GM) has been recognized as a key biological component of host health that contributes to the maintenance of immune regulation, metabolic homeostasis, and epithelial barrier function. Several studies are now demonstrating that biological sex has an influence on both GM composition and function, which might explain sex differences in disease predisposition, course, and treatment response. Evidence from both clinical and experimental studies indicates that sex hormones, genetics, and lifestyle-related exposures interact with GM to influence the development and progression of most common NCDs. Some research suggests that estrogens promote diversity in GM with anti-inflammatory immune responses, while androgens and male-abundant taxa are associated with pro-inflammatory conditions. However, the evidence in humans is largely confounded by other variables (such as age, genetics, and lifestyle) and should be interpreted with caution. Unique GM metabolites, such as short-chain fatty acids and secondary bile acids, can have distinct, sex-specific effects on inflammation, metabolic regulation, and even antitumor immunity. While the existence of a sex-gut microbiota axis is gaining increased support, most studies in humans are cross-sectional epidemiological studies with limited mechanistic evidence and little consideration for sex as a biological variable. Future works should prioritize longitudinal, sex-stratified studies and utilize multi-omics integrated approaches to identify causal pathways. Ultimately, integrating sex differences into GM-based approaches could provide new avenues for personalized strategies for the prevention and treatment of NCDs.

Indexed as

autoimmunitycancergut microbiotanon-communicable diseasesprecision medicinesex differences

Identifiers

PMID41157183
PMCPMC12565458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.